• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PD-L1 敲除小鼠揭示了耗竭 PD-L1 表达细胞在癌症治疗中的潜力。

PD-L1 mice reveal the potential of depleting PD-L1 expressing cells in cancer therapy.

机构信息

Genomic Instability Group, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.

Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.

出版信息

Aging (Albany NY). 2023 Mar 22;15(6):1791-1807. doi: 10.18632/aging.204598.

DOI:10.18632/aging.204598
PMID:36947705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10085585/
Abstract

Antibodies targeting the PD-1 receptor and its ligand PD-L1 have shown impressive responses in some tumors of bad prognosis. We hypothesized that, since immunosuppressive cells might present several immune checkpoints on their surface, the selective elimination of PD-L1 expressing cells could be efficacious in enabling the activation of antitumoral immune responses. To address this question, we developed an inducible suicidal knock-in mouse allele of (PD-L1) which allows for the tracking and specific elimination of PD-L1-expressing cells in adult tissues. Consistent with our hypothesis, elimination of PD-L1 expressing cells from the mouse peritoneum increased the septic response to lipopolysaccharide (LPS), due to an exacerbated inflammatory response to the endotoxin. In addition, mice depleted of PD-L1 cells were resistant to colon cancer peritoneal allografts, which was associated with a loss of immunosuppressive B cells and macrophages, concomitant with an increase in activated cytotoxic CD8 T cells. Collectively, these results illustrate the usefulness of PD-L1 mice for research in immunotherapy and provide genetic support to the concept of targeting PD-L1 expressing cells in cancer.

摘要

靶向 PD-1 受体及其配体 PD-L1 的抗体在一些预后不良的肿瘤中显示出令人印象深刻的反应。我们假设,由于免疫抑制细胞表面可能存在几种免疫检查点,因此选择性消除表达 PD-L1 的细胞可能有助于激活抗肿瘤免疫反应。为了解决这个问题,我们开发了一种可诱导的自杀性敲入小鼠 PD-L1()等位基因,可用于在成年组织中跟踪和特异性消除表达 PD-L1 的细胞。与我们的假设一致,从小鼠腹膜中消除表达 PD-L1 的细胞会增加对脂多糖(LPS)的败血症反应,这是由于对内毒素的炎症反应加剧。此外,耗尽 PD-L1 细胞的小鼠对结肠癌腹膜同种异体移植物具有抗性,这与免疫抑制 B 细胞和巨噬细胞的丧失以及激活的细胞毒性 CD8 T 细胞的增加有关。总的来说,这些结果说明了 PD-L1 小鼠在免疫治疗研究中的有用性,并为靶向癌症中表达 PD-L1 的细胞的概念提供了遗传支持。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/059b/10085585/39e508b60b3a/aging-15-204598-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/059b/10085585/b888773a458a/aging-15-204598-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/059b/10085585/6e39fb10852c/aging-15-204598-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/059b/10085585/db38659b1ef0/aging-15-204598-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/059b/10085585/bf485523f04e/aging-15-204598-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/059b/10085585/39e508b60b3a/aging-15-204598-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/059b/10085585/b888773a458a/aging-15-204598-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/059b/10085585/6e39fb10852c/aging-15-204598-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/059b/10085585/db38659b1ef0/aging-15-204598-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/059b/10085585/bf485523f04e/aging-15-204598-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/059b/10085585/39e508b60b3a/aging-15-204598-g005.jpg

相似文献

1
PD-L1 mice reveal the potential of depleting PD-L1 expressing cells in cancer therapy.PD-L1 敲除小鼠揭示了耗竭 PD-L1 表达细胞在癌症治疗中的潜力。
Aging (Albany NY). 2023 Mar 22;15(6):1791-1807. doi: 10.18632/aging.204598.
2
Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids.刺猬转录效应因子 GLI 介导 mTOR 诱导的胃癌类器官中 PD-L1 的表达。
Cancer Lett. 2021 Oct 10;518:59-71. doi: 10.1016/j.canlet.2021.06.007. Epub 2021 Jun 12.
3
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.ILT4 抑制可预防 TAM 和功能失调 T 细胞介导的免疫抑制,并增强 EGFR 激活的 NSCLC 中抗 PD-L1 治疗的疗效。
Theranostics. 2021 Jan 19;11(7):3392-3416. doi: 10.7150/thno.52435. eCollection 2021.
4
CD200 cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti-PD-1/PD-L1 therapy.肿瘤微环境中的CD200细胞毒性T淋巴细胞对于有效的抗PD-1/PD-L1治疗至关重要。
Sci Transl Med. 2023 Jan 18;15(679):eabn5029. doi: 10.1126/scitranslmed.abn5029.
5
Antitumor Effect of Korean Red Ginseng through Blockade of PD-1/PD-L1 Interaction in a Humanized PD-L1 Knock-In MC38 Cancer Mouse Model.人参抗肿瘤作用通过阻断人源化 PD-L1 敲入 MC38 肿瘤模型中的 PD-1/PD-L1 相互作用。
Int J Mol Sci. 2023 Jan 18;24(3):1894. doi: 10.3390/ijms24031894.
6
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.PD-L1 特异性辅助 T 细胞表现出有效的抗肿瘤反应:针对头颈部鳞状细胞癌中 PD-L1 的癌症免疫治疗新策略。
J Transl Med. 2019 Jun 20;17(1):207. doi: 10.1186/s12967-019-1957-5.
7
Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.日本血凝病毒-含程序性细胞死亡配体 1 的 siRNA 抑制胶质瘤的免疫抑制活性并引发抗肿瘤免疫反应。
Cancer Sci. 2021 Jan;112(1):81-90. doi: 10.1111/cas.14721. Epub 2020 Nov 25.
8
Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.基因工程改造的细胞囊泡,其表达CD64作为用于癌症免疫治疗的检查点抗体载体。
Theranostics. 2021 Apr 7;11(12):6033-6043. doi: 10.7150/thno.48868. eCollection 2021.
9
Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.具有免疫检查点抑制能力的抗癌 T 细胞药物的开发与功能分析。
IUBMB Life. 2020 Aug;72(8):1649-1658. doi: 10.1002/iub.2280. Epub 2020 Apr 7.
10
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.阻断白介素-17A 可增强微卫星稳定型结直肠癌对 PD-1 免疫治疗的反应。
J Immunother Cancer. 2021 Jan;9(1). doi: 10.1136/jitc-2020-001895.

本文引用的文献

1
Immune checkpoint inhibitors.免疫检查点抑制剂。
J Exp Med. 2021 Mar 1;218(3). doi: 10.1084/jem.20201979.
2
Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth.靶向程序性死亡受体配体1的嵌合抗原受体T细胞可抑制肿瘤生长。
Biomark Res. 2020 Jun 3;8:19. doi: 10.1186/s40364-020-00198-0. eCollection 2020.
3
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.帕博利珠单抗治疗晚期非小细胞肺癌患者的 5 年总生存结果:来自 I 期 KEYNOTE-001 研究的结果。
J Clin Oncol. 2019 Oct 1;37(28):2518-2527. doi: 10.1200/JCO.19.00934. Epub 2019 Jun 2.
4
Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice.基于纳米抗体的嵌合抗原受体 T 细胞靶向肿瘤微环境,抑制免疫活性小鼠的实体瘤生长。
Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7624-7631. doi: 10.1073/pnas.1817147116. Epub 2019 Apr 1.
5
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.KEYNOTE-001 研究中接受派姆单抗治疗的晚期黑色素瘤患者的 5 年生存结果。
Ann Oncol. 2019 Apr 1;30(4):582-588. doi: 10.1093/annonc/mdz011.
6
Regulation and Function of the PD-L1 Checkpoint.PD-L1 检查点的调控与功能
Immunity. 2018 Mar 20;48(3):434-452. doi: 10.1016/j.immuni.2018.03.014.
7
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.PD-1 和 PD-L1 抑制剂作为癌症免疫疗法的一种形式的发展:注册试验的综合回顾和未来的考虑。
J Immunother Cancer. 2018 Jan 23;6(1):8. doi: 10.1186/s40425-018-0316-z.
8
The peritoneal "soil" for a cancerous "seed": a comprehensive review of the pathogenesis of intraperitoneal cancer metastases.癌症“种子”在腹膜的“土壤”里:腹腔内癌症转移发病机制的全面综述。
Cell Mol Life Sci. 2018 Feb;75(3):509-525. doi: 10.1007/s00018-017-2663-1. Epub 2017 Sep 27.
9
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.肿瘤细胞上的程序性死亡配体1(PD-L1)足以在免疫原性肿瘤中实现免疫逃逸,并抑制CD8 T细胞的细胞毒性。
J Exp Med. 2017 Apr 3;214(4):895-904. doi: 10.1084/jem.20160801. Epub 2017 Mar 16.
10
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.癌症免疫疗法的原发性、适应性和获得性耐药性。
Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017.